Veozah Label Update: Boxed Warning for Hepatotoxicity Added

The FDA has updated the prescribing information for Veozah (fezolinetant) to include a boxed warning for hepatotoxicity, following reports of serious liver injuries. This oral neurokinin 3 receptor antagonist is used to manage menopause-related vasomotor symptoms, such as hot flashes. Healthcare providers are now required to evaluate hepatic function before treatment and monitor liver health regularly to ensure patient safety.